H.C. Wainwright analyst Andrew Fein lowered the firm’s price target on Neurocrine (NBIX) to $168 from $185 and keeps a Buy rating on the shares. The firm revisited its Ingrezza revenue assumptions considering the increasing dynamics of payer dynamics and increased competitive pressure and the spending assumptions given the growing pipeline.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- PepsiCo, Hormel, Neurocrine, Exelon, Aurora: Trending by Analysts
- Nike initiated, GM downgraded: Wall Street’s top analyst calls
- Needham upgrades Neurocrine on positive Crenessity survey
- Neurocrine upgraded to Buy from Hold at Needham
- Neurocrine upgraded to Outperform at RBC Capital following pullback